An international specialty pharma company

Meda is a leading international specialty pharma company. The company is represented in all of Europe and the US by its own marketing subsidiaries.

Meda's products are sold in 120 countries worldwide. During 2008, the company's net sales surpassed SEK 10 billion.

Meda's shares are traded on Nasdaq OMX Nordic Exchange in Stockholm.

	Nomination committee proposes re-election of all board members2010-02-24 16:30 - Pressrelease (pdf)
	Meda AB (publ) – 2009 year-end report2010-02-16 08:00 - Annual Financial Statement (pdf)
	Meda in-licenses exclusive rights to Xerese™2010-02-15 15:00 - Pressrelease (pdf)
	Meda in-licenses exclusive rights to Ceplene2010-01-11 08:00 - Pressrelease (pdf)
	FDA accepts NDA filing for Retigabine2009-12-30 14:07 - Pressrelease (pdf)
	Meda expands Axorid collaboration2009-12-30 10:00 - Pressrelease (pdf)
	Meda strengthens the financial headroom2009-12-07 11:10 - Pressrelease (pdf)
	Meda AB (publ) - Interim report, January–September 20092009-11-03 08:00 - Quarterly report (pdf)
	Retigabine filings completed in the US and Europe2009-11-02 14:13 - Pressrelease (pdf)
	Nomination committee appointed2009-10-26 15:00 - Pressrelease (pdf)

More news »

Priority therapy areas are
respiratory, cardiology, pain and inflammation, dermatology and CNS.

Read more »

Meda's shares are traded on Nasdaq OMX Nordic Exchange in Stockholm under Large Cap.